Senseonics (NYSE:SENS) announced today that it amended a loan and security agreement to increase its maximum borrowing capacity. The long-term implantable continuous glucose monitor (CGM) maker entered into the agreement with Hercules Capital. It increases its maximum borrowing capacity from $100 million to $140 million. In addition to $35 million of borrowings currently outstanding under […]
Implants
Senseonics announces $80M public offering
Senseonics (NYSE:SENS) today announced that it commenced an underwritten public offering to sell $80 million in common stock. The offering includes common stock and, for certain investors, pre-funded warrants to purchase common stock. Germantown, Maryland-based Senseonics expects to grant underwriters a 30-day option to purchase. up to an additional 15% of the total number of […]
More data backs Glucotrack long-term implantable CBGM
Glucotrack (Nasdaq:GCTK) today announced another publication of data supporting its long-term implantable glucose sensor. The latest data, published in The Journal of Diabetes Research, follows a publication last week supporting the system’s feasibility. This study evaluated the long-term accuracy and stability of the fully implantable blood glucose monitoring (CBGM) system in an in-vivo ovine model. […]
Senseonics launches Eversense 365 year-long CGM in Europe
Senseonics (Nasdaq:SENS) announced today that it initiated the first European launch of its Eversense 365 continuous glucose monitor (CGM). The launch comes a few months after the company picked up CE mark for the long-term, implantable CGM in January. The year-long sensor rests under the skin, meaning it can not be knocked off, minimizing inconveniences […]
Abbott has positive drug-eluting scaffold data
Abbott (NYSE:ABT) today shared promising 30-day results for its Esprit BTK everolimus-eluting resorbable scaffold system. Esprit features materials similar to dissolving sutures. Unlike metal stents, it’s not a permanent implant, providing support for blocked vessels only for a few months after the blockage is cleared. At that point, the vessel can remain open on its […]
Gluckotrack study supports feasibility of long-term CGM implant
Glucotrack (Nasdaq:GCTK) today announced the publication of a peer-reviewed scientific article evaluating its long-term glucose sensor. The article, published in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal, demonstrated the long-term in-vitro stability of the electrochemical glucose sensors used in the company’s fully implantable continuous blood glucose monitoring (CBGM) system. The company said […]
The first year-long CGM implant developer isn’t done yet
Senseonics VP of Product Development Hari Sree explains the tech behind the Eversense 365 continuous glucose monitor and what’s next in the pipeline.
Senseonics became the first company to bring a year-long continuous glucose monitor (CGM) to market with the launch of its Eversense 365 implantable system in 2024. The sensor system is different than existing transcutaneous sensors from Abbott and Dexcom, which use a small needle to measure glucose in the interstitial fluid under a patient’s skin […]
A look at the tech behind the world’s first year-long CGM with Senseonics
Long-term implantable continuous glucose monitor (CGM) innovation is abundant at Senseonics (Nasdaq:SENS). The Germantown, Maryland-based company launched Eversense 365, its implantable CGM in 2024. Eversense 365 rests under the skin for the duration of a year. Users can change the device’s external, silicone-based adhesive daily with almost no skin reactions. Eversense 365 is also an […]
Glucotrack to submit continuous blood glucose monitor for FDA IDE in early Q2
Glucotrack (Nasdaq:GCTK) today provided an update on the planned regulatory timeline for its continuous blood glucose monitor (CBGM). The Glucotrack device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution. Unlike traditional CGMs that measure glucose in interstitial fluid, […]
Vivani advances development of semaglutide implant
Vivani Medical (Nasdaq:VANI) provided updates this week on its progress and plans related to NPM-139, the company’s semaglutide implant. Alameda, California-based Vivani completed LIBERATE-1, which evaluated its miniature GLP-1 implant in obese and overweight subjects. The company initiated its LIBERATE-1 trial at two centers in Australia at the end of 2024. This study followed FDA […]
